Semi-Solid Dosage Contract Manufacturing Market Research Reveals Strong 10.4% CAGR Outlook Through 2030

The semi-solid dosage contract manufacturing market is set for impressive expansion in the coming years, driven by evolving pharmaceutical and cosmeceutical needs. As demand grows for specialized topical treatments and sustainable manufacturing practices, this sector is poised to transform significantly. Let's explore the current market size, key players, notable trends, and segmentation details shaping this dynamic industry.

Projected Growth Trajectory of the Semi-Solid Dosage Contract Manufacturing Market
The semi-solid dosage contract manufacturing market is forecasted to experience rapid growth, reaching a value of $29.52 billion by 2030. This expansion corresponds to a compound annual growth rate (CAGR) of 10.4%. Several factors are driving this uptrend, including the rising preference for personalized topical therapies, increased investments in innovative formulation technologies, and an expanding cosmeceutical outsourcing base. Additional contributors include a stronger emphasis on sustainable excipient use and heightened regulatory requirements ensuring manufacturing quality. Anticipated trends during this timeframe involve greater outsourcing of semi-solid drug production, increased demand for targeted dermatological products, adoption of flexible manufacturing setups, growth in bio-based and natural formulations, and a focus on compliance with regulatory standards.

The semi-solid dosage contract manufacturing market size has grown rapidly in recent years. It will grow from $17.97 billion in 2025 to $19.89 billion in 2026 at a compound annual growth rate (CAGR) of 10.7%. The growth in the historic period can be attributed to increasing pharmaceutical pipeline complexity, rising cost pressures on in-house manufacturing, expansion of topical and transdermal drug usage, growing demand for contract manufacturing services, availability of specialized cmo capabilities.

Download a free sample of the semi-solid dosage contract manufacturing market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25899&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Leading Companies Influencing the Semi-Solid Dosage Contract Manufacturing Industry
The landscape of semi-solid dosage contract manufacturing is shaped by a set of prominent companies, including The Lubrizol Corporation, Recipharm AB, Piramal Pharma Solutions Inc., Cambrex Corporation, ANI Pharmaceuticals, Aurigene Pharmaceutical Services Limited, DPT Laboratories Ltd., Douglas Pharmaceuticals Ltd., Mission Pharmacal Co., Bora Pharmaceuticals Co. Ltd., Ascendia Pharmaceuticals Inc., Fermion Oy, Ferndale Pharma Group, Sterling Pharmaceutical Services LLC, Aphena Pharma Solutions Inc., Eubioco LLC, Madras Pharmaceuticals, Quality CDMO, Axxelent Pharma Science, Tergus Pharma, MedPharm Ltd., and Alcami Corporation.

Significant Acquisition Enhancing Market Capabilities
In June 2024, US-based private equity firm Aterian Investment Partners acquired Contract Pharmaceuticals Limited Canada in a deal with undisclosed financial terms. This acquisition marks a crucial development for CPL, allowing the company to strengthen its workforce, technological resources, and operational processes. The move is expected to elevate CPL's market position and ability to deliver greater value as a trusted semi-solid dosage contract manufacturer serving global pharmaceutical clients. Contract Pharmaceuticals Limited is headquartered in Canada and specializes in semi-solid dosage contract manufacturing services.

View the full semi-solid dosage contract manufacturing market report:
https://www.thebusinessresearchcompany.com/report/semi-solid-dosage-contract-manufacturing-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Strategic Investments Spur Innovation and Market Expansion
Leading firms in the semi-solid dosage contract manufacturing sector are increasingly making strategic investments aimed at expanding their geographic reach and fostering innovation. Strategic investments involve long-term financial commitments designed to enhance a company's core competencies and competitive edge. A notable example occurred in March 2025 when LGM Pharma, a US-based semi-solid dosage contract manufacturer, announced an investment of over $6 million to expand its Rosenberg, Texas manufacturing facility. This upgrade will increase production capacity for liquid, suspension, semi-solid, and suppository formulations to meet rising demand within the domestic pharmaceutical market. The expansion supports LGM Pharma's growth in prescription drug development, including 505(b)(2) and ANDA programs, while maintaining compliance with FDA regulations and current good manufacturing practices. Importantly, the facility will remain fully operational throughout the construction period.

Detailed Segmentation of the Semi-Solid Dosage Contract Manufacturing Market
This report breaks down the semi-solid dosage contract manufacturing market into several key segments:
1) By Type: Topical, Transdermal, Oral
2) By Material Type: Synthetic, Natural, Bio-Based
3) By Company Size: Large Size Companies, Medium And Small Size Companies
4) By Therapeutic Application: Dermatology, Pain Management, Hormonal Therapy, Wound Care, Ophthalmic Disorders, Other Therapeutic Applications
5) By End Use: Pharmaceutical Companies, Cosmeceutical Companies, Other End Uses

Further subcategories include:
- Topical: Creams, Ointments, Gels, Lotions, Pastes, Foams
- Transdermal: Transdermal Gels, Transdermal Creams, Transdermal Sprays, Transdermal Emulsions, Medicated Patches
- Oral: Oral Gels, Oral Pastes, Oral Suspensions, Oral Emulsions, Oral Jellies

This detailed segmentation allows for a comprehensive understanding of the market's various facets and the specific needs addressed by different product types and user groups.

Key enhancements in our 2026 market reports include:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.